1. Home
  2. ECL vs REGN Comparison

ECL vs REGN Comparison

Compare ECL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecolab Inc.

ECL

Ecolab Inc.

HOLD

Current Price

$275.85

Market Cap

70.4B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$624.10

Market Cap

73.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECL
REGN
Founded
1923
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.4B
73.2B
IPO Year
2007
1995

Fundamental Metrics

Financial Performance
Metric
ECL
REGN
Price
$275.85
$624.10
Analyst Decision
Buy
Buy
Analyst Count
15
25
Target Price
$319.79
$830.16
AVG Volume (30 Days)
1.6M
1.1M
Earning Date
04-28-2026
04-29-2026
Dividend Yield
1.14%
0.55%
EPS Growth
N/A
8.19
EPS
1.52
6.75
Revenue
$16,081,200,000.00
$5,872,227,000.00
Revenue This Year
$9.97
$12.45
Revenue Next Year
$5.97
$10.13
P/E Ratio
$176.75
$91.55
Revenue Growth
2.16
20.82
52 Week Low
$243.15
$518.90
52 Week High
$309.27
$821.11

Technical Indicators

Market Signals
Indicator
ECL
REGN
Relative Strength Index (RSI) 64.25 46.18
Support Level $250.49 $610.60
Resistance Level $279.68 $640.82
Average True Range (ATR) 6.60 15.04
MACD 1.48 4.93
Stochastic Oscillator 84.34 66.35

Price Performance

Historical Comparison
ECL
REGN

About ECL Ecolab Inc.

Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, data center, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management and cooling solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: